Sales & Earnings

The Chinese biotech reported increased growth in its revenue fuelled by its portfolio of biologic drugs and biosimilars, with further plans for approvals around the world.

Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing pressures took their toll.

Amgen has revealed a program for a biosimilar rival to Keytruda, as it reported Q1 results that saw its biosimilars business grow by more than a tenth.

Formycon has shared its results for 2023, reporting revenue growth and exceeding projections for its working capital, as the company prepares for approvals in the coming year. 

Hikma will look to guarantee US generic competition to the powerful opioid brand Nucynta, albeit in the form of an authorized generic, as questions swirl over the appetite of at least one ANDA filer to compete on an equal footing, per the terms of a patent-litigation settlement deal.

It’s been a year since Biogen made it clear that it was ready to put its biosimilars business on the market. But despite signaling interest in the unit from multiple potential suitors over the past 12 months, the firm says it hasn’t yet received any “acceptable” offers, and may retain it after all.

Emerging out of its second Chapter 11 bankruptcy filing in the past four years, the company reported a slump in net sales despite positive signals in specific portfolios.

After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.

Belgian company Hyloris Pharmaceuticals has reported a 44% revenue increase in its 2023 results while doubling down on its long-standing ambition to have 30 portfolio assets in the near future.

Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.

With the war in Ukraine now in its third gruelling year, Stada has announced that it last year siphoned off its Russian interests to its parent company Nidda in a non-cash deal.

Coherus BioSciences has spoken in detail about its full suite of Udenyca pegfilgrastim biosimilar products and how it plans to return to growth and positive cash flow moving forward – although it cannot, for now, provide an estimate for 2024 revenues.

Endo’s generic and injectable segments struggled last year, with even lower projections for 2024, but potential financial restructuring may help the company rise from the ashes.

Sandoz’s biosimilars business was a big earner for the company in 2023. During the firm’s Q4 results call, CEO Richard Saynor provided a detailed breakdown of key products in the biosimilars portfolio and pipeline, as he highlighted sales growth of 26% in the most recent quarter.

An upbeat Sandoz pointed to growth across all its regions and businesses in 2023, as the firm delivered its first annual results as a standalone company.

Amneal continues to see a bright future in the biosimilars business as it looks for new portfolio additions, and gets ready for several complex product launches, some even yet to be disclosed, this year.